Mirati Therapeutics traded at $58.70 this Monday January 22nd, decreasing $0.10 or 0.17 percent since the previous trading session. Looking back, over the last four weeks, Mirati Therapeutics lost 0.51 percent. Over the last 12 months, its price rose by 22.52 percent. Looking ahead, we forecast Mirati Therapeutics to be priced at 56.93 by the end of this quarter and at 51.92 in one year, according to Trading Economics global macro models projections and analysts expectations.
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.